BIOBANK  login

Transkript.de

Transkript.de reports about the new partnership of CELLphenomics and KYAN Therapeutics. By combining KYAN’s technology platform, Optim.AI™ – which utilizes artificial intelligence to predict the effects of drug combinations and CELLphenomics‘ proprietary PD3D® technology, this partnership aims to offer an efficient approach to expedite drug development process in the biopharmaceutical industry.